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 Introduction 
 Botulinum toxin type A (BoNT-A) is a potent neuro-
toxin that has been used for more than 20 years to treat a 
variety of syndromes associated with elevated tension of 
striated or smooth muscles, including focal dystonias, 
spasticity and achalasia  [1–3] . BoNT-A reversibly inhibits 
release of acetylcholine at neuromuscular junctions, lead-
ing to a reduction in muscle tone and subsequent allevia-
tion of painful muscle spasms. Its beneficial effects in hy-
perhidrosis show that it also acts on peripheral acetylcho-
linergic neurons  [4] .
 Several studies have suggested that BoNT-A may be 
effective in the treatment of tension-type headache and 
migraine  [5, 6] . Migraine is an episodic neurovascular 
disorder with a global prevalence of 4–9% in men and 
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 Abstract 
 Aim: To determine if botulinum toxin type A (BoNT-A) injec-
tions can reduce the frequency and severity of migraines. 
 Methods: Patients (n = 127) were randomized to receive pla-
cebo or two doses of BoNT-A (Dysport  ). The primary end-
point was reduction in number of migraine attacks up to 
week 8 and between weeks 8 and 12 after injection. Patient 
diaries were used to record secondary endpoints, including 
frequency, severity and duration of migraine attacks.  Re-
sults: There was a mean reduction of 0.54 and 0.94 attacks/
month with placebo and BoNT-A, respectively, and absolute 
attack count was less in the verum group (3.6 vs. 4.2 attacks/
month), but this was not statistically significant. The patients’ 
global assessment of efficacy was significantly better than 
placebo in the high-dose group (p = 0.02) but no effects 
were seen for the other secondary efficacy parameters.  Con-
clusion: Our study showed a trend towards a reduced attack 
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11–25% in women  [7] . According to the criteria of the In-
ternational Headache Society (IHS), migraine is charac-
terized by severe, mostly unilateral headache attacks with 
duration of 4–72 h, of pulsating quality, moderate-to-se-
vere intensity, aggravated by routine physical activity and 
often associated with autonomic dysfunction and gastro-
intestinal symptoms  [8, 9] . Headaches can be preceded by 
a migraine aura, which is a complex of neurological 
symptoms that often present as temporary visual and/or 
sensory dysfunctions.
 There are many (published and unpublished) case re-
ports from patients who describe migraine improvement 
after treatment with BoNT-A for cosmetic purposes and 
who, after this positive experience, ask for repeat treat-
ment  [10] . To date, conflicting data have been obtained 
from clinical studies of BoNT-A for prophylactic treat-
ment of migraine. Most of the open-label studies have 
shown that BoNT-A has good efficacy in migraine ther-
apy, using either individualized or standardized proto-
cols  [11–13] . In all but one placebo-controlled prospective 
study  [14] , however, BoNT-A did not show any statisti-
cally significant superiority in reducing migraine fre-
quency or severity compared with placebo  [15–19] . A pos-
itive evidence for treatment with botulinum toxin in 
headache disorders remains to be proven up to date  [20] .
 To further investigate whether a standardized, prophy-
lactic scheme of BoNT-A injections can reduce the fre-
quency and severity of migraine and associated symptoms, 
we conducted a prospective, multicenter, randomized, 
double-blind, placebo-controlled trial of a highly purified 
 Clostridium botulinum type A toxin-hemagglutinin com-
plex (Dysport  ; Ipsen Ltd., Slough, UK) administered dur-
ing a single treatment session into cervical and/or pericra-
nial muscles.
 Patients and Methods 
 Patients 
 Men and women between 18 and 65 years of age were included 
in the study if they had at least a 1-year history of migraine with 
or without aura, a first manifestation under 50 years of age, and a 
stable frequency of 3–6 attacks per month according to IHS 1988 
criteria (the most recent criteria available at the time of the study) 
 [8] . Patients had not previously received BoNT-A, and no con-
comitant prophylactic migraine treatment was allowed during 
the study. Acute medication for migraine was allowed for a max-
imum of 10 days per month, although patients were restricted to 
only one type of escape medication that they preferably used (ei-
ther analgesic or triptan). Patients who experienced non-migraine 
headaches for more than 10 days per month before, but not after, 
injection were excluded from the study; thus the study was based 
on an intention-to-treat analysis. Women who were pregnant or 
not using adequate contraception were excluded, as were patients 
who had a history of alcohol or other drug abuse, who had previ-
ously experienced an adverse reaction to BoNT-A, or who were 
being treated with aminoglycoside antibiotics (or other medi-
cation affecting neuromuscular transmission), antidepressants, 
neuroleptics, antiepileptics or anticoagulants. Patients were also 
excluded if they had severe psychiatric disturbance, a skin disor-
der at the injection site, a predisposition to bleeding, or an an-
ticipated lack of compliance and cooperation.
 Study Design and Treatments 
 This randomized, double-blind, placebo-controlled study was 
carried out from March 2001 until October 2002 in 16 German 
centers. Patients were randomized to receive one of three treat-
ments: 210 units of Dysport injected into pericranial and cervical 
muscles, 80 units of Dysport injected into pericranial muscles 
plus placebo (0.9% NaCl) injected into cervical muscles, or pla-
cebo injected into both sets of muscles ( fig. 1 ) .1 Randomization 
was performed in blocks of two using Rancode (Version 3.6; IDV 
Datenanalyse und Versuchsplanung, Gauting, Germany), and 
blinding was ensured by preparation of the injections in a sepa-
rate room, by a third person, with allocation to treatment groups 
being noted and placed in sealed envelopes. Injections were per-
formed according to a fixed scheme, with 18 injection sites on the 
head and neck ( table 1 ). This investigator-initiated trial was con-
ducted in accordance with the Declaration of Helsinki. Approval 
was obtained from the ethics committee in all facilities that had 
such a committee, and written informed consent was obtained 
from each patient before the trial.
 Evaluation of Efficacy and Safety 
 The study involved six assessments, two prior to treatment 
(weeks –10 and –4), one at the time of randomization and injec-
tion of either active treatment or placebo (week 0, baseline), and 
three after the injection (weeks 4, 8 and 12). Patients kept a head-
ache diary for the entire 22 weeks, initially for the investigators to 
assess whether the inclusion criteria were met (weeks –10 to –4), 
and then for a 4-week baseline phase prior to treatment (week 0). 
Patients were asked to record each day the incidence, duration 
and severity of migraine attacks (on a Verbal Rating Scale: 1 = 
mild, 2 = moderate, 3 = severe, 4 = intolerable), pain intensity 
(0 = no headache, 1 = mild, 2 = moderate, 3 = severe headache), 
occurrence of aura or concomitant symptoms, and acute medica-
tion used for treatment of migraine attacks. At the initial visit 
(week –10) and at week 12, patients filled in Beck’s Depression 
Inventory. At week 12, patients and investigators also had to give 
a global rating of the treatment efficacy (1 = much better, 2 = 
slightly better, 3 = unchanged, 4 = slightly worse, 5 = much worse). 
In addition to a physical examination at each study visit, tender-
ness of cranial and facial muscles was assessed using a Total Ten-
derness Score  [24] .
 1  Note that the dosages given apply only to Dysport. Although BoNT-
A preparations are formulated as mouse LD 50 units, differences in assay 
methodology between different BoNT-A compounds mean that the units 
of measurement are not the same. When comparing data between studies, 
a ratio of between 2 and 3 units of Dysport to 1 unit of Botox  (Allergan, 
Inc., Irvine, Calif., USA) should be used  [21–23] . 
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 The primary endpoint was the reduction in the number of mi-
graine attacks during the previous 28 days at week 8 and week 12 
compared with the 28 days preceding baseline. A migraine was 
defined according to the IHS criteria  [8] , and in the patient dia-
ries, distinct attacks were counted if separated by a 24-hour head-
ache-free interval  [25] . The number of attacks at 8 weeks was cal-
culated as the mean number of attacks between days 28 and 55; 
the number of attacks at week 12 was the mean number of attacks 
between days 56 and 84.
 Secondary efficacy measures included: the number of days 
with migraine; mean headache duration; mean scores for mi-
graine severity and headache intensity from baseline to the target 
intervals; total attack duration and mean attack duration in hours; 
use of analgesics; migraine-related disability, and attacks with 
aura or autonomic concomitant symptoms. Secondary efficacy 
measures were preplanned in the statistical analysis plan; how-
ever, they were analyzed descriptively without adjustment of pri-
mary type error. Adverse events were recorded by the physician 
at three visits after injection (weeks 4, 8 and 12).
 Power Calculations and Randomization 
 To detect a reduction in attacks between baseline and target 
interval, in favor of verum, two groups of 50 patients were neces-
sary to result in a study power of 80%, assuming one attack less 
per 28 days on average, and a standard deviation of two attacks 
and a first type error   = 0.05 (PASS; NCSS, Inc., Kaysville, Utah, 
USA; two-sample power analysis adjusted for a Mann-Whitney 
test assuming a uniform data distribution). Assuming an expect-
ed dropout rate of 10–20% it was therefore planned to include at 
least 60 patients in each of the Dysport and placebo groups. Pa-
tients were randomized to two doses of Dysport for the explor-
atory analyses.
 Statistical Analyses 
 The statistical analysis of efficacy was based on all patients 
who received an injection of Dysport and who had a recorded 
number of migraine attacks before (weeks –4 to 0) and after 
(weeks 4–12) injection (intention-to-treat analysis). Missing data 
were replaced by carrying forward the last observation. For the 
primary efficacy endpoint, the non-parametric Mann-Whitney U 
test  [26] and the Wilcoxon-Mann-Whitney point estimator  [27] 
were used to assess the difference between BoNT-A and placebo, 
the analysis being performed using a two-group design. The same 
statistical methods were applied to the secondary efficacy vari-
ables, but they were analyzed in a strictly descriptive manner with 
reference to the primary parameter.
 All patients who received study medication were included in 
the safety analysis. Summary statistics were calculated separately 
for the number of adverse events.
M. occipitofrontalis
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 Fig. 1. Position of injection sites in pericranial and cervical mus-
cles. 
Table 1. Injection sites and doses per muscle per body side in the 
group that received 210 units of Dysport1
Muscle Injection
sites, n
Total dose per muscle
(mouse LD50 units)
Trapezius 3 45
Splenius capitis 2 20
Temporalis 2 20
Frontalis 1 10
Corrugator 1 10
Total per body side 9 105
LD50 lethal dose expected to cause the death of 50% of the 
animal population; standard deviation.
1 In the 80 units of the Dysport group, only the neck muscles 
were injected with placebo (0.9% NaCl); in the placebo group, all 
18 sites were injected with placebo (0.9% NaCl).
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 Results 
 Patient Disposition and Characteristics 
 The safety evaluation was performed on all 127 pa-
tients assessed for eligibility and injected with either 210 
units of Dysport (n = 32), 80 units of Dysport (n = 32) or 
placebo (n = 63) ( fig. 2 ). In total, 96% (n = 122) could be 
defined as the intention-to-treat population used for data 
analysis; 5 patients could not be fully analyzed as their 
headache diaries were incomplete. The total numbers of 
patients analyzed were 31 (210-unit group), 29 (80-unit 
group) and 62 (placebo group). The patients’ median age 
was 46 years (interquartile range: 38–55 years, i.e., 50% 
of subjects were within this age range). The mean age of 
those in the 210-unit group (42  8 12 years), however, was 
significantly younger than in the two other groups (49  8 
11 years for the 80-unit group, and 47  8 12 years for 
those in the placebo group) ( table 2 ). Male-to-female ra-
tio was not statistically different among the three groups. 
Mean frequency of migraine attacks at baseline in all 
groups was from 4 to 5 per month with an average dura-
tion of 36–40 h in the three groups.
 Treatment Efficacy 
 The primary efficacy parameter was the reduction in 
the number of migraine attacks within 28 days during the 
second and third 28-day interval after treatment (com-
bined mean of weeks 4–8 and weeks 8–12) compared 
with 28 days prior to baseline (weeks –4–0). Statistical 
analysis resulted in a mean of 0.54 fewer attacks for pa-
tients receiving placebo and 0.94 fewer attacks for those 
receiving verum (both verum-treated groups pooled). 
This difference was not statistically significant for either 
of the treatment groups (p = 0.25; two-sided Mann-Whit-
ney U test; p = 0.526; 95% confidence interval, 0.4191, 
0.6330, respectively).
 No differences from baseline to the target intervals oc-
curred among the treatment groups for the secondary ef-
Assessed for eligibility
n = 127
Included, randomised and
treated (safety data set)
n = 127
Patients analysed
(ITT data set)
n = 122
Patients treated
per protocol
n = 102
5 patients excluded
(missing diary data, i.e.
missing primary endpoint)
4 patients lost to follow-up
1 patient withdrew consent
20 patients excluded
(not allowed co-medication
for ≥10 days per month)
210 units of Dysport
n = 31
80 units of Dysport
n = 29
Placebo
n = 62
210 units of Dysport
n = 29
80 units of Dysport
n = 25
Placebo
n = 48 Fig. 2. Diagram showing the flow of par-
ticipants through the study. ITT = Inten-
tion-to-treat. 
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ficacy parameters. Furthermore, Beck’s Depression In-
ventory and the Total Tenderness Score revealed no dif-
ferences among the three groups. The patients’ global 
evaluation of treatment efficacy, however, was higher in 
the 210-unit group than in the placebo group: 69% (20/29) 
of the patients in the 210-unit group recorded their symp-
toms as slightly or much better and 24% (7/29) as un-
changed compared with 35% (21/60) recording slightly or 
much better and 57% (34/60) recording unchanged for 
those in the placebo group (p = 0.02) ( fig. 3 ). There were 
no differences among treatment groups with respect to 
the investigators’ global evaluation of efficacy.
 The recommended headache-free interval between 
migraine attacks has not been clearly defined, with rec-
Table 2. Patient demographics and baseline migraine characteristics
210 units of
Dysport (n = 31)
80 units of
Dysport (n = 29)
Placebo
(n = 62)
p value
Sex
Male 7 (23%) 4 (14%) 9 (15%)
Female 24 (77%) 25 (86%) 53 (85%) 0.56
Mean age, years 8 SD 42812 49811 47811 0.04
Mean time since first migraine onset, years 8 SD 23814 29813 27812 0.08
Mean attack frequency per month, n 8 SD 581 481 581 0.41
Mean attack duration for all patients, h 8 SD1 36823 37820 40822 0.51
Mean number of days with analgesics per month, days 8 SD 783 682 782 0.16
1 HS, 1988 criteria (the most recent criteria available at the time of the study).
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ommendations citing a 48-hour interval or a separation 
between attacks of 1 headache-free day (which may be 
 ! 48 h) according to a patient’s headache diary  [25] . There-
fore, although a 24-hour headache-free interval was pre-
planned for the study, we also performed post-hoc analy-
ses using a 48-hour headache-free interval to define two 
separate migraine attacks. For weeks 4–8, the results 
showed a pronounced difference in the mean number of 
migraine attacks experienced by patients in the 210-unit 
group (2.7 attacks), patients in the 80-unit group (2.8 at-
tacks) and patients in the placebo group (3.4 attacks). 
Pooled analysis showed a descriptive superiority in favor 
of verum compared with placebo (p = 0.01, rank analysis 
of variance) ( fig. 4 ).
 Safety Analyses 
 Treatment was generally well tolerated in the 127 pa-
tients analyzed for safety. Adverse events occurred in 
38% (12/32) and 13% (4/32) of patients in the 210- and 80-
unit groups, respectively, and in 17% (11/63) of patients 
receiving placebo. The most frequent adverse event was 
neck weakness in 8 patients (13%) who received verum 
and 1 patient (2%) receiving placebo (p  ! 0.05, pooled 
analysis). Ptosis was reported for 2 patients who received 
verum (3%, pooled analysis; 1 patient for each dose).
 Discussion 
 The difference in treatment efficacy between the two 
doses of Dysport and placebo was not statistically sig-
nificant with regard to the primary endpoint (reduction 
in the number of migraine attacks compared with base-
line). Thus, this study did not confirm the findings of 
several open-label  [11–13] and placebo-controlled dou-
ble-blind trials  [6, 14, 16, 18] that reported efficacy of bot-
ulinum toxin against migraine severity, the amount of 
analgesics needed or the occurrence of accompanying 
symptoms. However, as in the studies by Silberstein et al. 
 [14] and Goebel et al.  [6] , we saw a trend towards a reduc-
tion in the frequency of migraine attacks with verum.
 A difference in favor of active treatment was seen in 
the patients’ global evaluation of treatment efficacy for 
the higher dose of 210 units Dysport. The potency of the 
two BoNT-A preparations used in different studies should 
be highlighted. Two to three units of Dysport are approx-
imately equivalent to 1 unit of Botox  [28] . Consequently, 
the lower dose in our study (80 units of Dysport) may be 
considered to be equivalent in potency to the 25 units of 
Botox used in the Silberstein trial  [14] . The patients’ pos-
itive evaluation of the higher dose in our study is opposed 
to the results of the Silberstein trial, where only the low 
dose of BoNT-A was effective, although this may be ac-
counted for by differences in injection sites. In the Silber-
stein trial, injections were limited to facial muscles  [14] , 
whereas in our study the high-dose regimen also includ-
ed the neck musculature.
 In some studies, an explanation of the negative results 
was the possible influence of allowing headache prophy-
lactic treatment  [29, 30] . The withdrawal of any prophy-
lactic migraine treatment before the baseline period, 
however, had no positive impact on our study results. 
 Additional post-hoc analyses using a 48-hour head-
ache-free interval were carried out due to conflicting def-
initions of the duration of the headache-free interval be-
tween two attacks in the Guidelines for Controlled Trials 
for Drugs in Migraine, 2000  [25] : ‘A migraine attack 
which is interrupted by sleep, or temporarily remits, and 
then recurs within 48 h should be recorded as one attack. 
A practical solution to differentiating these using diary 
entries over the previous month is to count as distinct at-
tacks only those that are separated by an entire day head-
ache-free’, which corresponds to a 24-hour interval. Us-
ing the 48-hour definition, we found a significant reduc-
tion for the patients treated with botulinum toxin in 
migraine frequency occurring between weeks 4 and 8 af-
ter injection. We did, however, not see any influence on 
migraine severity, the use of acute medication or any as-
sociated symptoms. This highlights the importance of 
precise definitions that are sometimes missing in publi-
cations on migraine trials and suggests that the relevant 
international guidelines need to be clearer in this re-
spect. 
 Differences in inclusion criteria and methodology 
among studies may also account for differences in results. 
Patients in the trial by Goebel et al.  [15] experienced both 
migraine and tension-type headaches, and were included 
only when they had increased tenderness of pericranial 
muscles. Furthermore, injections were administered into 
individually chosen trigger points. Use of a standardized 
injection scheme, as in our study and that of Evers et al. 
 [19] , seems to be less efficient. Also the different distribu-
tion of the dose to all pericranial (210 units group) or lim-
ited only to the facial muscles (80 units group), as in Saper 
et al.  [30] , did not have an effect on the headache symp-
toms.
 In most trials, as in ours, a single treatment and a 3-
month follow-up period are applied. However, Aurora et 
al.  [29] could also not show a positive effect of prophylac-
tic treatment of episodic migraine after multiple treat-
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ments and a follow-the-pain treatment paradigm in pre-
defined muscle areas. Our study did not detect increased 
sensitivity of head and neck muscles in any patient group, 
as evaluated by the Total Tenderness Score. A missing ef-
fect of BoNT-A treatment on Total Tenderness Scale was 
also described by Vo et al.  [31] . Our patient cohort may 
not, therefore, seem to be particularly predisposed to mi-
graine caused by muscular trigger factors. The question 
of whether patients with a particular type of migraine 
may respond to BoNT-A treatment still needs further 
clarification. The clear indication of BoNT-A efficacy 
against migraine frequency observed in our standardized 
and non-selective approach suggests the need for a more 
thorough investigation of factors that might predispose 
patients to a better response to the treatment.
 The safety profile of Dysport was good: except for neck 
weakness, which increased with BoNT-A treatment in 
the pooled analysis, there were no marked differences in 
reported adverse events between the groups.
 Our study did not demonstrate significant improve-
ment of BoNT-A treatment compared with placebo in re-
ducing the frequency of monthly migraine attacks and 
hence supports the results of other negative randomized 
studies in prophylactic headache treatment with botuli-
num toxin. According to a recent survey on evidence-
based medicine on the use of botulinum toxin for head-
ache disorders  [32] , prospective primary outcome mea-
sures are in general not met, although secondary outcomes 
are positive in some studies. The conclusion states that 
the treatment effectiveness is considered ‘unproven’. 
However, ongoing and further studies should address the 
question of whether a specific subset of patients who 
 experience migraine might benefit from BoNT-A treat-
ment.
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